Entering text into the input field will update the search result below

Second Quarter Profit Help Pfizer Ahead Of Their Major Restructuring

Jul. 31, 2013 8:30 AM ETPFE
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pfizer Inc. (NYSE:PFE) saw a rise in their profit of the second quarter. Despite the expectations from analysts, the drug manufacturing firm came of better in their second quarter, ahead of their reconstruction.

It was a big boost for Pfizer Inc, as it prepares to reconstruct itself by separating its business into three individual sections.

During the same quarter last year, the income came down from 59 cents per share to 56 cent per share. Pfizer Inc's income came down from $4.45 billion to only $4 billion. This year, stock market analysts were expecting another fall. However, the company was able to see a rise in their revenue from $12.97 billion to $13.01 billion.

Thomson Reuters's conducted a poll. According to the analysis, the company expected to earn 55 cent per share, but apparently the drug maker firm came out better.

A rise in profit was quite an abetment for the company, especially as it came after a major announcement from company on Monday, deciding to reconstruct itself into three divisions. According to statement released by the company on Monday, it will break itself into three separate business segments. Here are the details of company's restructure.

The three divisions of Pfizer Inc. will be responsible for handling separate production lines. The first division will handle production of rare disease, pain, neuroscience and gender-based drugs. The second division will be taking care of cancer related drugs, vaccination, and various other health care products. While on the other hand, third division of the company will launch itself into new emerging markets such as, China and Brazil, with an intention to expand.

According to a statement released by the chief executive and chairman of the company, "Our new commercial operating model will allow each business to respond to market dynamics in a better way. It will add focus and visibility to our business, optimizing the capabilities to deliver a better value to both our shareholders and patients." List of Tens (www.listoftens.com/) is a good website to read interesting articles.

The rise in Pfizer Inc.'s in second-quarter profit was good news for the company after the drop in sales of their famous product Lipitor. The cholesterol lowering drug is also not under the exclusive patent of the company anymore.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.